Moderna stock on track for 10% weekly gain after US bird flu death
Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.
Moderna stock seesaws as first US bird flu death puts vaccine development in focus
Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.
Abzena Strengthens Board With Appointment Of Biopharma Industry Leader, Dr Moncef Slaoui
Dr Moncef Slaoui currently serves as an advisor to Medicxi and is on the Board of Directors of several companies including Cedar Health, Arcturus Therapeutics, Altesa, Zephyr AI and Vicebio. He has ...
MedPage Today44m
FDA Adds Guillain-Barre Syndrome Warning to Two RSV Vaccines
The CDC recommends a single dose of any FDA-approved RSV vaccine for all adults ages 75 years and older, as well as for 60- ...